|MDACC Study No:||2012-0223 (clinicaltrials.gov NCT No: NCT01340794)|
|Title:||A Phase 2 Study of Pazopanib (GW786034) in Patients with Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma |
|Principal Investigator:||Camilo Jimenez|
|Study Description:||The goal of this clinical research study is to learn if Votrient (pazopanib) |
can help to control metastatic pheochromocytoma or paraganglioma. The safety
of this drug will also be studied.
Pazopanib is designed to block the growth of blood vessels that supply
nutrients needed for tumor growth. This may prevent or slow the growth of